Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (121-130 of 198) with videos related to

Pageof 20
Sort By:
NEJM Evidence|October 28, 2025
Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerAlicia K Morgans, Soumyajit Roy, Angela Y Jia, et al.
Cancer Causes & Control : CCC|April 19, 2018
Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort studySylvia H J Jochems, Frits H M van Osch, Raoul C Reulen, et al.
Clinical and Experimental Pharmacology & Physiology|November 30, 2004
Nitroreductase: a prodrug-activating enzyme for cancer gene therapyPeter F Searle, Ming-Jen Chen, Longqin Hu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancerRobert Hugh Jones, Karim Fizazi, Nicholas D James, et al.
European Urology Focus|February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)Susan Halabi, Bin Luo, Chenxi Yu, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
Proteomics. Clinical Applications|August 2, 2011
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancerRichard T Bryan, Wenbin Wei, Neil J Shimwell, et al.
Nature|June 19, 2024
Single-cell and spatial atlases of spinal cord injury in the Tabulae ParalyticaMichael A Skinnider, Matthieu Gautier, Alan Yue Yang Teo, et al.
BJU International|March 5, 2013
A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 yearsRichard T Bryan, Maurice P Zeegers, Eline H van Roekel, et al.
Pageof 20

Showing results (121-130 of 198) with videos related to

Sort By:
Pageof 20
NEJM Evidence|October 28, 2025
Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerAlicia K Morgans, Soumyajit Roy, Angela Y Jia, et al.
Cancer Causes & Control : CCC|April 19, 2018
Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort studySylvia H J Jochems, Frits H M van Osch, Raoul C Reulen, et al.
Clinical and Experimental Pharmacology & Physiology|November 30, 2004
Nitroreductase: a prodrug-activating enzyme for cancer gene therapyPeter F Searle, Ming-Jen Chen, Longqin Hu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancerRobert Hugh Jones, Karim Fizazi, Nicholas D James, et al.
European Urology Focus|February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)Susan Halabi, Bin Luo, Chenxi Yu, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
Proteomics. Clinical Applications|August 2, 2011
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancerRichard T Bryan, Wenbin Wei, Neil J Shimwell, et al.
Nature|June 19, 2024
Single-cell and spatial atlases of spinal cord injury in the Tabulae ParalyticaMichael A Skinnider, Matthieu Gautier, Alan Yue Yang Teo, et al.
BJU International|March 5, 2013
A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 yearsRichard T Bryan, Maurice P Zeegers, Eline H van Roekel, et al.
Pageof 20